Welcome to Lab Test Consult

You can log in and post your comments

Share your knowledge and experience!

Member Login
Lost your password?

Vivacta Plans Large Scale Manufacture of Point-of-Care Cartridges

January 12, 2012


Vivacta Limited, the medical diagnostics company with a revolutionary
system for point‐of‐care testing, announced today it plans large scale
production of its disposable cartridges to meet commercial demand ahead
of establishing strategic relationships with commercial partners.

Vivacta’s cartridges incorporate an innovative piezofilm sensor.
Vivacta’s technology platform enables the development of next-generation
point-of-care diagnostics and monitoring systems. The finger-prick tests
provide lab-quality measurement of disease markers and drugs in
whole-blood in under ten minutes.

To lead the new initiative, Vivacta has appointed Andrew Whittle as
Process Engineering Manager. Mr Whittle was Operations Manager and Site
Leader at ThermoFisher Scientificprior to his appointment and brings
in-depth knowledge of establishing an IVD (in vitro diagnostics)
manufacturing cell to Vivacta.

Dr Tim Carter, CEO, said, “The creation of our pilot facility in 2009
gave Vivacta the strategic advantage of being able to develop new tests
on consistently manufactured materials and demonstrated to potential
commercial partners the scaleability of our process. Now we see the need
to establish executable plans for commercial-scale manufacturing and we
are delighted that Andrew Whittle has agreed to join us and lead this

In recognition of her role in achieving ISO 13485:2003 compliance for
Vivacta’s existing pilot facility and the importance of her work in
quality management, Sonja Jones has been promoted to Director of Quality
and Regulatory Affairs.

About Vivacta

Vivacta Limited is applying its expertise in piezofilm technology to
develop a range of new generation high performance PoC diagnostics able
to deliver quantitative readings within 10 minutes from a single pin
prick of blood.

The Company’s platform technology exploits the piezoelectric effect by
which thermal perturbations on a piezofilm surface cause an electric
charge to be produced. The measurement of this electric charge enables
monitoring of chemical activity – or rate of binding between antibody
and analyte – in an assay. In harnessing this piezofilm platform
technology, Vivacta has developed PoC diagnostic products able to
produce and present sensitive, precise and fully quantitative results,
equivalent to those produced in laboratories.

Each test requires only a finger prick sample, providing actionable
results in 10 minutes or less. Rapid point-of-care testing avoids the
delay caused by sending samples away to a remote laboratory for analysis
and is essential where speed of diagnosis or frequent testing
(monitoring) is medically necessary or economically desirable.

Vivacta has generated an independent intellectual property position of
over 10 patent families protecting the use of piezofilms in diagnostic
assays. Vivacta’s investors include Albion Ventures, HBM BioVentures,
IDInvest (formerly AGF), Spark Ventures and Viking.

For more information please visit www.vivacta.com

Article source: http://finance.yahoo.com/news/vivacta-plans-large-scale-manufacture-091700987.html


Related posts:

  1. Lynntech Developing Inexpensive Sample Prep, Testing Platforms for Point-of-Care MDx
  2. OPKO Health Announces Commencement of U.S. Clinical Trial for Point-of-Care Prostate Specific Antigen Test
  3. OPKO Health Begins Clinical Trial For Point-of-Care PSA Test
  4. Idaho Tech Demos Clinical Utility of FilmArray Respiratory Dx; Plans to Add Blood, GI Panels
  5. High blood pressure may point to hidden health problems for kids in the ER
  6. Cancer care overhaul revealed


New post


April 2019
« Aug    


Recent comments

    Contact Sign In

    Email Marketing You Can Trust